Jade Biosciences, Inc.
NASDAQ:JBIOBiotechnology
-$0.21 today
- Market cap
- $1.07B
- Beta
- 1.45
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$2.24
Volume 0.79M
Average 0.83M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Jade Biosciences, Inc.
NASDAQ:JBIO
Intrinsic Alpha fair value
Locked
Current Price
$15.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Vera Therapeutics, Inc. NASDAQ:VERA | $2.03B | $28.10 | Not rated | -6.8 | -10.40% |
First Tracks Biotherapeutics Inc NASDAQ:TRAX | $1.98B | $47.10 | Not rated | -6.1 | — |
MoonLake Immunotherapeutics NASDAQ:MLTX | $1.06B | $12.50 | Not rated | -5.4 | -20.31% |
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $621.76M | $3.92 | Not rated | -8.2 | +42.28% |
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM | $348.58M | $9.86 | Not rated | -7.5 | -25.66% |
Kyverna Therapeutics, Inc. NASDAQ:KYTX | $312.31M | $5.05 | Not rated | -3.1 | -45.57% |
Eledon Pharmaceuticals, Inc. NASDAQ:ELDN | $171.87M | $2.12 | Not rated | -5.5 | +30.97% |
Dogwood Therapeutics, Inc. NASDAQ:DWTX | $42.43M | $1.11 | Not rated | -0.2 | -74.54% |
Continue the stock analysis
Jump to another research area for this company.